Immunotec Collects Three Gold Globee Awards as Patent Portfolio and Revenue Expand
The Texas-based direct selling company was recognised in the Achievement in Research & Development category at the 18th Globee Awards for Innovation, according to a Direct Selling News report. Days later it added two more gold statuettes at the 16th Globee Awards for Business, against a backdrop of rising revenue and an expanding intellectual property portfolio.

Three gold awards in two ceremonies
Immunotec has received a gold Globee Award in the Achievement in Research & Development category at the 18th Globee Awards for Innovation, also known as the Golden Bridge Awards. The recognition was reported by the trade publication Direct Selling News on 6 November 2026.
The Globee Awards for Innovation programme evaluates the measurable innovation performance of organisations worldwide, regardless of size category or industry sector.
On 12 November 2026, the company collected two further gold Globee Awards at the 16th Globee Awards for Business: one in the Achievement in Rapid Growth & Scaling category, and one in the HealthTech, Life Sciences or Biotech Product or Service of the Year category, the latter also tied to its flagship product, Immunocal.
Research converted into patents
According to the judges, the research and development award acknowledges the company's long-term investment in scientific research and its work exploring potential application areas for Immunocal, a cysteine-rich whey protein isolate.
The official winners' list states that Immunotec has converted decades of Immunocal research into three United States patents. The company obtained one US patent in April 2024, and added two more US patents in June 2026.
Immunotec's research and intellectual property portfolio has recently extended into neurological and neuropsychiatric fields. In total, the company's patent portfolio comprises 81 patents.
Growth figures behind the business award
Company revenue rose from approximately $145 million to $200 million between 2023 and 2025, while EBITDA increased from roughly $10 million to close to $25 million over the same period.
Immunotec's European network sales grew by 66 percent over the past two years. The company currently operates in 31 global markets with customers and independent consultants.
Over the past five years, Immunotec has shipped more than 10 million boxes of Immunocal to customers worldwide. The company is headquartered in The Woodlands/Houston, Texas, in the United States.
![[uk-house-ad] webinar4me banner 970Γ90](/_next/image?url=%2Fapi%2Fmedia%2Ffile%2Fuk-webinar4me-970x90.png&w=3840&q=75)
![[uk-house-ad] MLM System banner 970Γ90](/_next/image?url=%2Fapi%2Fmedia%2Ffile%2Fuk-mlmsystem-970x90.png&w=3840&q=75)

![[uk-house-ad] webinar4me banner 728Γ90](/_next/image?url=%2Fapi%2Fmedia%2Ffile%2Fuk-webinar4me-728x90.png&w=3840&q=75)
![[uk-house-ad] MLM System banner 728Γ90](/_next/image?url=%2Fapi%2Fmedia%2Ffile%2Fuk-mlmsystem-728x90.png&w=3840&q=75)

